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Abstract
Eicosapentaenoic acid (EPA) has garnered attention after the success of the 
REDUCE-IT trial, which contradicted previous conclusions on EPA for cardiovascu-
lar disease risk. Here we first investigated EPA's preventative role on hyperglycemia 
and hyperinsulinemia. EPA ethyl esters prevented obesity-induced glucose intoler-
ance, hyperinsulinemia, and hyperglycemia in C57BL/6J mice. Supporting NHANES 
analyses showed that fasting glucose levels of obese adults were inversely related to 
EPA intake. We next investigated how EPA improved murine hyperinsulinemia and 
hyperglycemia. EPA overturned the obesity-driven decrement in the concentration 
of 18-hydroxyeicosapentaenoic acid (18-HEPE) in white adipose tissue and liver. 
Treatment of obese inbred mice with RvE1, the downstream immunoresolvant me-
tabolite of 18-HEPE, but not 18-HEPE itself, reversed hyperinsulinemia and hy-
perglycemia through the G-protein coupled receptor ERV1/ChemR23. To translate 
the findings, we determined if the effects of RvE1 were dependent on host genetics. 
RvE1's effects on hyperinsulinemia and hyperglycemia were divergent in diversity 
outbred mice that model human genetic variation. Secondary SNP analyses further 
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1 |  INTRODUCTION
Circulating levels of eicosapentaenoic acid (EPA, 20:5n-
3) are generally low in the western population.1 Therefore, 
increased intake of EPA and other n-3 polyunsaturated 
fatty acids (PUFA) is hypothesized to ameliorate a range 
of risk factors that contribute toward cardiometabolic dis-
eases.2 Notably, EPA has garnered attention as the recent 
REDUCE-IT trial showed EPA ethyl esters (Vascepa) 
substantially reduced the risk of cardiovascular disease 
in statin-treated patients with elevated triglycerides.3 As 
a consequence, the FDA approved EPA ethyl esters for 
cardiovascular disease risk reduction for select clinical 
populations. This overturned the dogma on n-3 PUFAs as 
having no efficacy for lowering the risk of cardiovascular 
diseases.4
The effects of n-3 PUFAs on insulin sensitivity and glu-
cose tolerance remain strongly debated. Several randomized 
clinical trials have failed to establish the benefits of increased 
n-3 PUFA intake for treating subjects with insulin resis-
tance, which may be due to a range of factors including poor 
controls, a focus on treatment rather than prevention, and 
often a neglect for a diversified human genetic makeup.2,5,6 
Furthermore, a unifying mechanism by which n-3 PUFAs 
such as EPA prevent insulin resistance remains unclear. Many 
studies have relied on heterogenous mixtures of n-3 PUFAs 
despite evidence that EPA and its long chain counterpart do-
cosahexaenoic acid (DHA) are not structurally or functionally 
identical.7-9 To further complicate matters, many preclinical 
studies rely on levels of n-3 PUFAs that are not easily achiev-
able in humans.2 Finally, very little is known about the thera-
peutic potential of EPA-derived metabolites, which represent 
the next generation of n-3 PUFA research. Thus, the overarch-
ing goal of this study was to address these limitations.
We first studied if pure EPA ethyl esters, modeling human 
pharmacological intake, prevent obesity-induced metabolic 
impairments using C57BL/6J mice. Supporting translational 
analyses on the association between fasting glucose lev-
els and dietary intake of PUFAs were conducted using data 
from the National Health and Nutrition Examination Survey 
(NHANES).10 We then conducted mass spectrometry-based 
metabolomic and lipidomic analyses to identify targets of EPA 
ethyl esters, which led to the study of 18-hydroxyeicosapentae-
noic acid (18-HEPE) and its downstream metabolite, resolvin 
E1 (RvE1). RvE1 belongs to a family of PUFA-derived endoge-
nous metabolites known as specialized pro-resolving mediators 
(SPMs) that are potent immunoresolvants.11-16 We specifically 
investigated if exogenous treatment of 18-HEPE followed by 
studies with RvE1 could reverse hyperinsulinemia and hy-
perglycemia through the G-protein coupled receptor ERV1/
ChemR23. Given that RvE1 is an immunoresolvant, immune 
profiling experiments using flow cytometry addressed if RvE1 
mitigated metabolic impairments in obesity via an improve-
ment in adipose tissue inflammation. Finally, to translate the 
research, we determined if the metabolic effects of RvE1 were 
dependent on the host genome, which is critical to investigate 
as humans are genetically heterogenous. To do so, we utilized 
diversity outbred (DO) mice, a unique mouse population that 
models human genetic diversity.17 In parallel, we conducted 
supporting SNP analyses by mining the Ensembl database to 
identify genetic variation of EPA and RvE1 metabolizing genes 
in humans.
2 |  MATERIALS AND METHODS
2.1 | Animal models, diets, and 18-HEPE/
RvE1 administration
All murine experiments adhered to IACUC guidelines estab-
lished by The University of North Carolina at Chapel Hill and 
East Carolina University for euthanasia and humane treatment 
confirmed extensive genetic variation in human RvE1/EPA-metabolizing genes. 
Collectively, the data suggest EPA prevents hyperinsulinemia and hyperglycemia, 
in part, through RvE1's activation of ERV1/ChemR23 in a host genetic manner. The 
studies underscore the need for personalized administration of RvE1 based on ge-
netic/metabolic enzyme profiles.
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in addition to the NIH Guide for the Care and Use of Laboratory 
Animals. Euthanasia relied on CO2 inhalation followed by 
cervical dislocation. C57BL/6J male mice of 5-6  weeks 
of age were fed lean control (10% kcal from lard, Envigo 
TD.160407) or high-fat (HF) (60% kcal from lard, Envigo 
TD.06414, Indianapolis, IN) diet in the absence or presence 
of EPA (Cayman, ≥93%, Ann Arbor, MI) ethyl esters (Envigo 
TD.160232) for 15 weeks. EPA in the HF diet accounted for 
2% of total energy. For select studies, C57BL/6J male mice 
were purchased obese from Jackson at 18 weeks of age. They 
were acclimatized by feeding lean (10% lard, D12450B) or HF 
(60% lard, D12492) diets (Research Diets, New Brunswick, NJ) 
for an additional 2-3 weeks prior to conducting experiments. 
DO male mice (Jackson, Bar Harbor, ME) from generation 33 
were obtained at 4 weeks of age and acclimated for 2 weeks. 
The DO population is derived from 144 Collaborative Cross 
lines obtained from Oak Ridge National Laboratory at genera-
tions F4-F12 of inbreeding.17 For some experiments, mice were 
administered 300  ng of 18-HEPE or RvE1 purchased from 
Cayman Chemical per day for four consecutive days.18
The ERV1/ChemR23 mutant mice were generated by 
CRISPR/Cas9-mediated genome editing. Benchling software 
was used to identify Cas9 guide RNAs flanking the coding 
sequences of the Cmklr1 (ERV1/ChemR23) gene. Three guide 
RNAs at each end of the target sequence were selected for ac-
tivity testing. The 5′ and the 3′ guide RNAs were designed 
to target near the 3′ end of ERV1/ChemR23 intron 2 and the 
3′ UTR region after the stop codon in ERV1/ChemR23 exon 
3, respectively. Guide RNAs were cloned into a T7 promoter 
vector followed by in vitro transcription and spin column pu-
rification. A mouse embryonic fibroblast cell line was trans-
fected with guide RNA and Cas9 protein to perform functional 
testing. The guide RNA target site was amplified from trans-
fected cells and analyzed by T7 Endonuclease 1 assay. Guide 
RNAs selected for genome editing in embryos were 5sg81T 
(protospacer sequence 5′- GAGATCGTTCACAACCC-3′) 
and 3sg81T (protospacer sequence 5′-gCGGCCCAGGGA 
CGCCTA-3′). A donor oligonucleotide of sequence 5′- CAT 
ACGAATGCAAAATAAAGACAAGAAATGGCA 
A A AG G G GAGAT C GT T CACA ATA AT G G GAGA 
CATGCCGGGAGCCTTTGGGAATGCTCCAATGC 
CCACTGAATTTTG-3′.
was included to facilitate homologous recombination to 
produce a deletion event. However, the founder animal did not 
have the same deletion junction as the donor oligonucleotide, 
suggesting the oligonucleotide did not participate in the dele-
tion allele resolution in that founder. C57BL/6J zygotes were 
electroporated with 1.2 μM Cas9 protein, 94.5 ng/mL each 
guide RNA and 400 ng/mL of donor oligonucleotide and im-
planted in recipient pseudopregnant females. Resulting pups 
were screened by PCR for the presence of a deletion allele. 
One male founder was identified with a precise deletion be-
tween the cut sites of the electroporated guide RNAs. The 
founder was mated to wild-type (WT) C57BL/6J females to 
establish a colony with the deletion allele. ERV1/ChemR23 
animals were detected by PCR with primers Cmklr1-5ScF1 
(5′-GGAGCAGGAAACAGAATAGGAC-3′), Cmklr1-
3ScF1 (5′-ATCACCTTCTTCCTCTGCTGG-3′) and 
Cmklr1-3ScR1 (5′-GGTTTGACTGTCATGTTGCCATA-3′). 
The schematic illustrating the generation of the ERV1/
ChemR23 mutant allele by CRISPR/Cas9-mediated genome 
editing is described below in the results. These mice and WT 
littermate controls were also fed diets from Envigo.
2.2 | Body mass and insulin/glucose 
measurements
Metabolic studies including echo-magnetic resonance imaging 
(MRI) experiments were conducted as previously described.19 
Briefly, mice were fasted for 5 hours prior to the establishment 
of baseline glucose values with a glucometer. For the glucose 
tolerance test, 2.5 g of dextrose (Sigma-Aldrich, St. Louis, MO) 
per kg lean mass was administered intraperitoneally.
2.3 | Studies with diversity outbred mice
Since every DO mouse is genetically unique, each mouse 
served as its own control. Baseline fasting insulin/glucose 
measurements were recorded once each DO mouse achieved 
~14 g of fat mass as measured by Echo-MRI. The mice were 
then allowed 1  week to recover and subsequently i.p. in-
jected for four consecutive days with 300 ng RvE1 per day.18 
Fasting glucose and fasting insulin were again measured after 
RvE1 administration.
2.4 | Untargeted mass spectrometry-based 
metabolomics
Adipose tissue and liver were homogenized using a bead ho-
mogenizer and prepared for metabolomics using previously 
described methods.19 Samples were analyzed using liquid 
chromatography/mass spectrometry (LC/MS) and raw data 
were extracted and processed using Agilent Technologies 
Mass Hunter Profinder Version B.08.00 (Profinder) software 
in combination with Agilent Technologies Mass Profiler 
Professional Version 14 (MPP) as previously described.20-22 
An in-house database containing METLIN, Lipid Maps, 
Kyoto Encyclopedia of Genes and Genomes (KEGG), and 
Human Metabolomics Database (HMDB) was used to an-
notate metabolites based on exact mass, isotope ratios, and 
isotopic distribution with a mass error cutoff of 10  ppm. 
This corresponds to annotation at Metabolomics Standards 
Initiative (MSI) level 3.23
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To visualize clustering between the dietary groups we 
ran a principal component analysis (PCA) using all metab-
olites. We then determined statistically significant metabo-
lites between obese mice and obese mice supplemented with 
EPA. One of the samples from the HF diet (HF_105) was 
an outlier from all the other samples and was excluded from 
analyses. We then calculated fold changes (EPA/HF). Next, 
using the validated significant metabolites with Log2 fold 
changes  ±  1.5 we standardized the abundances of the me-
tabolites by assigning a Z-score for each sample based on the 
distribution of the given metabolite. We utilized the Z-scores 
to generate heatmaps annotated with the classification of 
each metabolite.
2.5 | Targeted mass spectrometry-based 
metabololipidomics
Analyses of PUFA-derived metabolites of visceral white 
adipose tissue, liver, and heart was conducted as previously 
described.24 Lipid mediators were extracted using Strata-X 
33-μm 30 mg/1 mL SPE columns (Phenomenex, Torrance, 
CA). Quantitation of lipid mediators was performed using 
two-dimensional reverse phase HPLC tandem mass spec-
trometry (liquid chromatography/tandem mass spectrom-
etry). All standards and internal standards used for the LC/
MS/MS analysis were purchased from Cayman Chemical 
(Ann Arbor, Michigan, USA). All solvents and extraction 
solvents were HPLC grade or better.
2.6 | Flow cytometry analyses of differing 
immune cell populations in adipose tissue
Epididymal visceral adipose tissue was mechanically 
chopped and then digested with collagenase Type 4, DNAse 
1, and 0.5% fatty acid free bovine serum albumin in phos-
phate buffered saline (PBS) for 50  minutes at 37°C in an 
incubator shaker (120 RPM). Next, 0.5M EDTA was added 
with RPMI media and the cells were passed through a 70-μm 
cell strainer rinsed with 2% fetal bovine serum (FBS) in 
PBS. The cells were centrifuged at 1400 RPM for 5  min-
utes at 4°C, primary adipocytes were aspirated off from 
the top layer of the supernatant and the pellet containing 
the stromal vascular cells (SVC) was then incubated with 
red blood cell lysis buffer for 1  minute on ice. Two per-
cent FBS-PBS was added to the SVCs and centrifuged at 
1400 RPM for 5 minutes at 4°C and then passed through a 
40-μm cell strainer. SVCs were stained with the following 
fluorophore-tagged antibodies obtained from BioLegend 
(San Diego, CA): Zombie Aqua, CD45 (PerCP-Cy5.5), 
CD11b (FITC), CD19 (APC-Cy7), F4/80 (PE), and MHCII 
(BV421). The following SVC subsets were analyzed using 
a BD LSRII flow cytometer: CD45+CD11b-CD19+ (B 
cells), CD45+CD11b+F4/80+MHCII+ (macrophages), 
CD45+CD11b+F4/80+MHCII- (macrophages). All data were 
analyzed in FlowJo and gates were drawn from fluorescence 
minus one controls.
2.7 | Analyses of NHANES database
The 2013-2014 NHANES database was mined for daily av-
erage intake of PUFAs with respect to age, sex, and BMI. 
Nutrient intake for NHANES is measured via the 2013-2014 
USDA's Food and Nutrient Database for Dietary Studies 
(FNDDS). NHANES utilizes the FNDDS to code individual 
food/beverages and portion sizes reported by participants 
and the FNDDS includes nutrient values for calculating 
nutrient intake from ingested foods. We used Rv3.4.4 with 
the RNHANES package to retrieve the NHANES database. 
Graphical packages ggpubr and ggplot2 were used to generate 
all graphs and statistical annotations. The “Dietary Interview 
- Total Nutrient Intakes” section of the NHANES database 
was used to retrieve PUFA intake measurements based on 
a 24-hour dietary recall questionnaire. OGTT 2-hour glu-
cose measurements were retrieved from the “Current Health 
Status” section, where BMI was retrieved from “Body 
Measures.” Tertiles of PUFA intake were calculated cor-
responding to the probability of intake at 33.3%, 67%, and 
100% of the range. Normality and homogeneity of variance 
were tested with the Shapiro-Wilks test and Bartlett test, re-
spectively. Since the dataset did not satisfy the assumptions 
of normality and heteroscedasticity, we utilized a Kruskal-
Wallis test followed by a Wilcoxon pairwise test to measure 
significant differences between tertiles of PUFA intake.
2.8 | SNP analyses
We used the Biomart tool to mine the Ensembl Variation 98 
Human Short Variants (GRCh38.p13) database for single nu-
cleotide polymorphisms (SNPs) with minor allele frequencies 
at or above 5% that are contained within the 1000 genomes 
project or the NCBI dbSNP archive. We used the ggplot2 
package in R v3.4.4 to plot all the minor allele frequencies 
by each allele for every gene and chromosome. White lines 
in the graph represent a break/gap in the minor allele fre-
quency (MAF) distribution, for example, a gene may contain 
MAFs ranging from 0.05 to 1.5 then 2.5 to 4.5 with a “break” 
between 1.5 and 2.5 gap. The distance between SNPs of dif-
ferent genes on the chromosomes was determined using the 
base pair location at the last SNP of the first gene and the 
first SNP of the second gene. Distances below 500 kilobases 
were considered as having a higher likelihood for genetic 
linkage, as described by the HapMap project Haploview tool. 
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SNPs were mined in the following genes: PTGS2/COX2 
(ENSG00000073756), CYP1A1 (ENSG00000140465), 
CYP1A2 (ENSG00000140505), CYP2E1 (ENSG0000013 
0649), CYP2C8 (ENSG00000138115), CYP2C9 (ENSG00 
000138109), CYP2C18 (ENSG00000108242), CYP2C19 
(ENSG00000165841), CYP2J2 (ENSG00000134716), 
CYP4F2 (ENSG00000186115), CYP4F3 (ENSG000001 
86529), CYP4F8 (ENSG00000186526), CYP4F12 (ENS 
G00000186204), CYP2S1 (ENSG00000167600), CMKLR1/ 
ChemR23 (ENSG00000174600), LTB4R/BLT1 (ENSG00 
000213903), ALOX12/15 (ENSG00000108839 & ENSG0 
0000161905), ALOX5 (ENSG00000012779), ALOX5AP/ 
FLAP (ENSG00000132965) and LTA4H (ENSG00000 
111144).
2.9 | Statistics
Data were analyzed using Graph Pad Prism Version 7.0. 
Statistical significance relied on one-way or two-way 
ANOVAs followed by a post hoc Tukey HSD test if the data 
satisfied the assumptions of normality and homogeneity of 
variance tested by the Shapiro-Wilks test and Bartlett test, 
respectively. Data that failed the assumption of heterosce-
dasticity were analyzed using a Welch ANOVA followed 
by a pairwise Welch T test with a Bonferroni p-value ad-
justment. Datasets that did not display normal distributions 
were analyzed with a Wilcoxon pairwise test. Studies as 
a function of time that passed the assumptions of normal-
ity and heteroscedasticity were analyzed with a two-way 
ANOVA. For clarity, additional description of analyses 
are also included with each corresponding methods section 
above. For all analyses, P < .05 was considered statistically 
significant.
3 |  RESULTS
3.1 | EPA limits hyperglycemia, 
hyperinsulinemia, and improves glucose 
tolerance of obese male C57BL/6J mice
We first determined if dietary administration of EPA could 
prevent obesity-induced metabolic impairments of obese 
male mice. The approach relied on pure ethyl esters of EPA 
and not mixtures of EPA with DHA that can confound the 
data. Mice consuming a HF diet in the absence or presence 
of EPA had similar increases in total mass and fat mass com-
pared to lean controls (Figure 1A). Inclusion of EPA in the 
diet of obese mice prevented the development of obesity-
driven glucose intolerance (Figure 1B), as quantified by the 
area under the curve (Figure 1C). Relative to the HF diet, EPA 
restored the impairment in fasting glucose (Figure 1D) and 
improved fasting insulin levels (Figure 1E). The HOMA-IR 
score was also lowered with EPA in the diet, relative to the 
mice consuming the HF diet (Figure 1F).
3.2 | EPA is associated with improved 
glucose levels in obese humans in a sex-
dependent manner
To translate the murine data, we analyzed the relation be-
tween EPA intake and blood glucose levels during an OGTT 
in obese humans using data from NHANES. Increased EPA 
intake was associated with lower glucose levels between the 
first tertile and the third tertile for obese males (Figure 2A) 
but not females (Figure 2B). Furthermore, we investigated if 
there was a relationship between DHA and glucose levels. In 
obese males (Figure 2C) and females (Figure 2D), there was 
no association between DHA and blood glucose levels.
The metabolism of EPA relies on some of the same 
immune responsive and metabolic enzymes used by n-6 
PUFAs such as linoleic acid (LA).25,26 Thus, we further 
mined the NHANES data to determine if there was a rela-
tionship between the ratio of LA and EPA on fasting glucose 
levels. Tertiles of the LA to EPA ratio are plotted for obese 
men (Figure 2E) and women (Figure 2F). The positive as-
sociation between EPA and glucose levels was diminished 
and strikingly, at the highest ratio of LA to EPA in men 
(Figure 2E), but not women (Figure 2F), blood glucose lev-
els were increased relative to the first two tertiles. We also 
analyzed the ratio of arachidonic acid (AA) to EPA given 
that AA is also a highly prevalent n-6 PUFA. Analyses of 
the tertiles of the AA to EPA ratio showed no association 
with blood glucose levels in men (Figure 2G) and women 
(Figure 2H).
3.3 | Mice consuming EPA have a distinct 
metabolome compared to obese mice in the 
absence of EPA
As the mechanism of action for EPA ethyl esters is likely 
to be pleiotropic, we conducted metabolic profiling of mice 
consuming the experimental diets. PCA plots revealed a clear 
distinction between the control, HF, and HF  +  EPA ethyl 
ester diets for visceral white adipose tissue (Figure 3A). EPA 
ethyl esters were predominately incorporated into triglycer-
ides with some uptake into diglycerides and phosphatidyl-
choline (Figure 3B,C). In the liver, PCA plots also showed 
a clear distinction between the HF and HF  +  EPA ethyl 
ester diets (Figure 3D). EPA ethyl esters appeared to have 
a broad effect on the liver metabolome (Figure 3E,F). EPA 
acyl chains were likely distributed into triglycerides, phos-
phatidylcholine, phosphatidylethanolamine, and anandamide 
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(Figure 3F). Overall, these results showed that EPA ethyl es-
ters incorporated into several lipid pools, which would then 
differentially influence metabolic pathways, particularly in 
the adipose tissue and liver. The full metabolite names, P-
values, fold changes, and quantitations are in Supporting 
Tables S1 and S2.
F I G U R E  1  EPA ethyl esters prevent obesity-induced impairments in glucose tolerance, fasting glucose and fasting insulin levels of C57BL/6J 
mice. A, Body composition measured by Echo-MRI. B, Glucose tolerance test performed by intraperitoneal injection of glucose after a 5 h fast. C, 
Area under the curve (AUC), calculated by integration of the curves in B normalized to baseline values. D, Fasting glucose and (E) fasting insulin 
levels after a 5 h fast. F, HOMA-IR scores. For all measurements, male mice consumed a lean control (Con) diet (O), a high-fat (HF) diet (∆), or 
a HF diet supplemented with EPA ethyl esters (□). Measurements were conducted at week 13 of intervention. Values are means ± SD. *P < .05, 
**P < .01, ***P < .001, ****P < .0001 from one-way ANOVA followed by Tukey's multiple comparisons test except B, which was a two-way 
ANOVA followed by a post hoc test
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3.4 | 12-HEPE and 18-HEPE levels are 
lowered with obesity and reversed with EPA
We next conducted targeted metabololipidomic analyses to 
further study the effects of EPA on the adipose tissue and 
liver lipidomes. The HF diet and HF diet + EPA modulated 
several n-3 and n-6 PUFA-derived metabolites in these tis-
sues. The HF diet amplified several white adipose tissue 
n-6 PUFA-derived mediators relative to the lean control 
(Figure  4A). These included 11(12)-EET, 14(15)-EET, 
15R-LXA4, 6-α-PG, 8-iso-15R-PGF2α, 8-iso-PGF2α, car-
boxylic TXA2, 8S-HETE, and 15S-HETE. Inclusion of 
EPA in the HF diet also amplified some but not all of these 
metabolites (Figure  4A). Markedly, the HF diet lowered 
the levels of the EPA-derived 18-HEPE, which was re-
versed with EPA in the diet. 18-HEPE levels were elevated 
by ~5.6 and ~32.6-fold relative to the lean and HF diets, 
respectively (Figure  4A). EPA also strongly upregulated 
the concentration of 12-HEPE in white adipose tissue by 
~58-fold.
In the liver, the n-6 PUFA-derived LXA4 and PGE2 
were increased with the HF diet relative to the lean control 
(Figure 4B). Notably, 12-HEPE and 18-HEPE levels were 
undetectable with the HF diet compared to the control. The 
HF + EPA diet lowered PGE2 and 9-HODE levels and in-
creased LXB4 levels relative to the HF diet. The HF + EPA 
diet also decreased the levels of 13-HODE compared to the 
lean and HF diets (Figure 4B). EPA dramatically increased 
the levels of 12-HEPE and 18-HEPE compared to the lean 
and HF diets (Figure 4B). EPA also elevated the levels of 
14-HDHA and 17-HDHA relative to the HF diet.
We also analyzed the heart to determine if the effects of 
EPA were limited to white adipose tissue and liver. In the 
heart, EPA had some modest effects on the number of n-6 
PUFA derived metabolites modified relative to the HF diet 
(Supporting Figure S1). Similar to white adipose tissue and 
F I G U R E  2  Glucose levels are inversely related to EPA intake in obese men but not women and are dependent on the ratio of LA to EPA. 
NHANES data on 2-hour glucose measurements (mg/dL) from an OGTT were stratified by tertiles of EPA intake in grams for obese (A) males 
and (B) females. DHA intake is also depicted for (C) males and (D) females. The range of EPA intake for males was 0.0-0.009 g for tertile 1, 
0.01-0.068 g for tertile 2, 0.069 g, and above for tertile 3. For females, the intake is 0-0.009 for tertile 1, 0.01-1.51 g for tertile 2, 1.52 g, and above 
for tertile 3. The range of DHA intake for males is 0.01-0.05 g for tertile 1, 0.06-1.49 g for tertile 2, and 1.5 g and above for tertile 3. The range of 
DHA intake for females was 0.01-0.03 g for tertile 1, 0.04-2.35 g for tertile 2, and 2.36 g and above for tertile 3. Subjects were adults (18 years and 
older) and had a BMI of 30 and above. Tertiles of the ratio of LA to EPA are presented for obese (E) males and (F) females. Tertiles of the ratio of 
AA to EPA are presented for obese (G) males and (H) females. The tertiles correspond to 33%, 67%, and 100% of the range of LA to EPA intake 
for subjects older than 18 and a BMI of 30 and above. Values are means ± SEM *P < .05, **P < .01, ***P < .001 from Wilcoxon pairwise test. 
Number of subjects for each tertile is listed on the x-axis
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liver, EPA increased the concentration of 12-HEPE and 18-
HEPE by up to 11-27-fold relative to the lean and HF diets, 
respectively (Supporting Figure S1). Overall, the robust 
amplification of 18-HEPE levels set the basis for subsequent 
experiments with 18-HEPE and RvE1, the downstream bio-
active metabolite of 18-HEPE.
F I G U R E  3  EPA ethyl esters have a distinct metabolomic profile in white adipose tissue and liver of obese C57BL/6J male mice. C57BL/6J 
male mice consumed a control (Con), high-fat (HF) and HF + EPA ethyl ester diet. A, PCA plot of validated adipose tissue metabolites between 
control, HF, and HF + EPA samples. B, Heatmap of Z-scores from significant adipose tissue metabolites with ± 1.5 fold-change. C, Log2 fold 
change graph of EPA-containing (20:5) adipose metabolites. D, PCA plot of validated liver metabolites between control, HF, and HF + EPA 
samples. E, Heatmap of Z-scores from significant liver metabolites with ± 1.5 fold-change. F, Log2 fold change graph of EPA-containing 
(20:5) adipose metabolites. Heatmap legends on the right hand side of (B) and (E) show each metabolite's classifications: triglyceride (TG), 
diacylglycerol (DG), phosphatidylethanolamine (PE), lysophosphatidylethanolamine (LysoPE), phosphatidic acid (PA), phosphatidylcholine 
(PC), phosphatidylserine (PS), phosphatidylglycerol (PG), phosphatidylinositol (PI), arachidonoylethanolamine (AEA), cholesterol (CL), and 
docosahexaenoic acid (DHA). Full metabolite names are provided in the supplemental
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3.5 | RvE1 but not 18-HEPE treatment 
improves hyperinsulinemia and controls 
hyperglycemia of inbred mice in a manner that 
is dependent on the receptor ERV1/ChemR23
We investigated the effects of 18-HEPE and RvE1 on fast-
ing insulin and fasting glucose levels using C57BL/6J mice 
(Figure 5A). For this specific study (Figure 5A-G), we used 
C57BL/6J mice that were obtained obese from Jackson 
Laboratories. 18-HEPE treatment of obese mice had no effect 
on body weight (Figure 5B) compared to the mice on a HF 
diet. 18-HEPE treatment also had no effect on fasting glucose 
(Figure 5C) and fasting insulin levels (Figure 5D) compared 
to mice on the HF diet. Experiments with RvE1 similarly 
F I G U R E  4  EPA ethyl esters reverse the effects of murine obesity on the concentration of 18-HEPE. Mass spectrometry-based 
metabololipidomic analyses of (A) visceral white adipose tissue and (B) liver. Metabolites from eicosapentaenoic acid (EPA), docosahexaenoic 
acid (DHA), linoleic acid (LA), and arachidonic acid (AA) are depicted in the heat map. Male C57BL/6J mice consumed experimental diets for 
15 weeks. N = 4-5 mice per diet. Data are average. *P < .05, **P < .01, ***P < .001 as compared to a control diet and +P < .05, ++P < .01 as 
compared to the high-fat diet. Statistical analyses for these data are described in the methods section
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F I G U R E  5  RvE1 but not 18-HEPE treatment improves obesity-driven impairments in fasting glucose and insulin of C57BL/6J mice mediated 
by the receptor ERV1/ChemR23. A, Study design for experiments using C57BL/6J mice or ERV1/ChemR23 knockout mice and their wild-type 
(WT) littermate controls administered 18-HEPE, RvE1 or vehicle control after being fed a high-fat diet or lean control diet. B, Body weight, (C) 
fasting glucose, and (D) fasting insulin levels of male C57BL/6J mice in the presence of 18-HEPE or vehicle control. E, Body weight, (F) fasting 
glucose, and (C) fasting insulin levels of C57BL/6J male mice in the presence of RvE1 or vehicle control. Experiments shown in B-G were with 
mice purchased obese from Jackson Laboratories. H, Illustration of ChemR23 deletion allele and genotyping. I, Body weight (J) fasting glucose, 
and (K) fasting insulin levels of male WT and ERV1/ChemR23 knockout (KO) mice consuming a lean control diet (Con) or high-fat (HF) diet in 
the presence of RvE1 or vehicle control. All measurements were made at 13-14 weeks of dietary intervention. N = 6-18 mice per diet. Values are 
means ± SD. *P < .05, **P < .01, ***P < .001, ****P < .0001 by one-way ANOVA followed by Tukey's multiple comparisons test
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showed no effect on body weight (Figure  5E). However, 
RvE1 treatment improved fasting glucose (Figure  5F) and 
fasting insulin levels (Figure 5G) relative to obese mice.
We next tested the hypothesis that the effects of RvE1 
was mediated by one of its two receptors known as ERV1/
ChemR23. Therefore, we generated ERV1/ChemR23 knock-
out (KO) mice and WT littermates to measure the effects 
of RvE1 on hyperinsulinemia and hyperglycemia induced 
by consumption of a HF diet. Figure 5H depicts the ERV1/
ChemR23 deletion allele. Body composition did not differ 
between obese WT and ERV1/Chem23 KO mice adminis-
tered vehicle control or RvE1 (Figure 5I). RvE1 treatment im-
proved fasting glucose levels of WT but not ERV1/ChemR23 
KO mice compared to obese mice (Figure 5J). We also tested 
fasting insulin levels in a subset of our WT and KO mice via 
an ELISA. Fasting insulin levels were improved in response 
to RvE1 in WT obese mice but not in ERV1/ChemR23 KO 
obese mice relative to obese mice that received the vehicle 
control (Figure 5K).
Mechanistically, immune cells such as B lymphocytes 
and macrophages in white adipose tissue have a central role 
in maintaining metabolic homeostasis. Furthermore, previ-
ous work shows that resolvin D1 improves glycemic control 
by targeting the number of M1- and M2-like macrophages 
in white adipose tissue.12 Thus, we investigated if RvE1 was 
preventing the enrichment of key immune cells in visceral 
white adipose tissue. The flow cytometry gating strategy 
is depicted in Figure  6A and fluorescence minus one con-
trols are shown in Supporting Figure S2. For this select 
study, we only compared mice consuming a HF diet in the 
absence or presence of RvE1 as significant pooling of lean 
mice was required. Strikingly, the analyses revealed RvE1 
had no effect on the percentage of CD45+CD11b-CD19+ B 
cells (Figure  6B), CD45+CD11b+F4/80+MHCII+ macro-
phages (Figure 6C), or CD45+CD11b+F4/80+MHCII- mac-
rophages (Figure 6D). Similarly, there was no effect of RvE1 
on the number of CD45+CD11b-CD19+ B cells (Figure 6E), 
CD45+CD11b+F4/80+MHCII+ macrophages (Figure 6F), or 
CD45+CD11b+F4/80+MHCII- macrophages (Figure  6G). 
We also probed if RvE1 had any impact on select inflamma-
tory and metabolic transcripts. qRT-PCR analysis revealed 
no effect of RvE1 on the expression of adiponectin, Tnfα, 
IL10, and GLUT-4 (data not shown).
3.6 | Host genetics define the treatment 
response to RvE1
Humans are metabolically heterogeneous with a diversified 
genetic makeup. Therefore, in order to translate the findings 
with inbred C57BL/6J mice, we determined whether host ge-
netic differences lead to variations in the fasting insulin and 
fasting glucose response to RvE1. For these studies, we used 
the translational DO mouse model that mimics human genetic 
diversity and variability.17 Similar to the human population, 
administration of a HF diet led to large variations in body 
weight gain of DO mice. Thus, we optimized an experimental 
design (Figure 7A) to selectively measure the effects of RvE1 
on fasting insulin and fasting glucose. Mice that achieved 
~14 g of fat mass (measured via Echo-MRI) over the course 
of the dietary intervention with a HF diet were used for these 
studies. The rationale for selecting ~14  g of fat mass was 
based on the studies with obese C57BL/6J mice (Figures 1 
and 5) that were in this range of fat mass. Body weight gain 
of the DO mice is depicted in Supporting Figure S3. Relative 
to baseline, RvE1 improved fasting glucose (Figure 7B) and 
fasting insulin (Figure 7C) levels in only half of the obese 
DO mice. In contrast, using the same experimental design 
with C57BL/6J mice, fasting glucose (Figure 7D), and fast-
ing insulin (Figure 7E) were more uniformly improved in re-
sponse to RvE1 treatment.
The results with the DO mice led us to further investi-
gate if there is strong genetic variation in RvE1- and EPA-
metabolizing genes in humans. We mined the Ensembl 
database containing the dbSNP archive and 1000 genomes 
data (Supporting Table S3). We extracted all the CYP450 
enzymes that have the capacity to metabolize EPA, fur-
ther downstream enzymes leading to the production of 
E-series resolvins (COX2, ALOX5, FLAP, ALOX12/15, 
and LTA4H), and the two RvE1 receptors, ChemR23, and 
BLT1 (Figure 7F).27-29 The CYP450 genes contained many 
SNPs in close proximity (<500 kilobases) on the same chro-
mosome, indicating a higher probability for genetic linkage, 
these include: CYP2C18 and CYP2C19 (~27  Kb apart), 
CYP2C19 and CYP2C9 (~84  Kb), CYP2C9 and CYP2C8 
(~47  Kb), CYPA1A1 and CYPA1A2 (~24  Kb), CYP4F8 
and CYP4F3 (~10  Kb), CYP4F3 & CYP4F12 (~10  Kb), 
and CYP4F12 and CYP4F2 (~181 Kb) (Figure 7G). We also 
found a large range of minor allele frequencies where SNPs 
for each gene are contained in chromosomes 1, 10, 12-15, 
17, and 19 (Figure 7G,H). Genes with lower ranges of MAF 
ranging from 0.05 (5%) to 0.38 (38%) include BLT1, COX2, 
CYP2J2, CYP1A1, and CYP1A2. Surprisingly, all other 
genes contained many high MAFs with numerous SNPs in 
the 0.4 (40%)-0.5 (50%) range (Figure 7G,H). Taken together, 
these results showed high population variance in EPA—and 
RvE1—metabolizing genes.
4 |  DISCUSSION
There is growing evidence from humans and rodents that obe-
sity impairs the biosynthesis of SPMs and their precursors, 
which are predominately generated from dietary n-3 PUFAs 
including EPA.13,19,30,31 The loss of SPMs contributes toward 
a range of cardiometabolic complications including chronic 
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inflammation, hepatic steatosis, insulin resistance, suscep-
tibility to infection, and delayed wound healing.12,14,24,31-34 
Therefore, there is an unmet need to understand how specific 
dietary n-3 PUFAs through the biosynthesis of their down-
stream metabolites regulate outcomes in cardiometabolic and 
inflammatory diseases.
Our study suggests that administration of EPA ethyl esters 
can prevent hyperinsulinemia and control hyperglycemia, in 
part, through the actions of RvE1 in a host genetic dependent 
manner. Given that EPA has a wide range of targets, its effects 
are likely pleiotropic and could involve other mechanisms 
such as remodeling of the microbiome, regulating brown 
F I G U R E  6  The metabolic improvement with RvE1 is not driven by a reduction in the enrichment of select inflammatory immune cells 
in white adipose tissue. A, Flow cytometry gating strategy for B lymphocytes and macrophage populations in the white adipose tissue of obese 
C57BL/6J male mice purchased from Jackson Laboratories. All measurements were made at 13-14 weeks of dietary intervention. The percentage 
of (B) CD45+CD11b-CD19+ B cells (C) CD45+CD11b+F4/80+MHCII+ macrophages and (D) CD45+CD11b+F4/80+MHCII- macrophages. The 
number of (E) CD45+CD11b-CD19+ B cells, (F) CD45+CD11b+F4/80+MHCII+ macrophages and (G) CD45+CD11b+F4/80+MHCII- macrophages. 
N = 6-7 mice per diet. Values are means ± SD
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adipose tissue metabolism, targeting transcription factors, or 
biophysical changes of immune cell plasma membranes.35-38 
A notable outcome were the data from the NHANES anal-
yses, which underscore the need for preventative precision 
nutrition studies with EPA. Longitudinal studies with EPA 
that are focused on prevention, prior to the onset of insulin 
resistance, are limited. One pilot study demonstrated that 
administration of n-3 PUFAs to healthy human volunteers 
prevented insulin resistance induced with a glucocorticoid.39 
The NHANES analyses revealed those subjects with lowest 
consumption of EPA, but not DHA, had the highest glucose 
levels in a sex-specific manner. The positive effects of EPA 
were mitigated when the intake of LA was high, which is 
common in the western diet. While these data are associative, 
they point to the importance of discriminating EPA from DHA 
and accounting for LA levels in clinical studies and trials. LA 
biosynthesis and metabolism requires some of the same en-
zymes used for EPA synthesis and metabolism, including the 
endogenous biosynthesis of downstream metabolites such as 
RvE1.25,26 Indeed, a recent study showed that LA inhibited 
F I G U R E  7  Host genetics have a critical role in the metabolic response to RvE1. A, Schematic representation of study design with diversity 
outbred mice. Fasting glucose and insulin measurements were obtained prior to (baseline) and after 4 days of RvE1 administration. B, Fasting 
glucose and (C) fasting insulin levels after a 5 h fast. Corresponding studies with C57BL/6J mice using the same experimental design of 
intervention are depicted for (D) fasting glucose and (E) fasting insulin. All data are plotted as the fold change in glucose and insulin relative 
to baseline. N = 19 DO mice and N = 6 C57BL/6J mice. **P < .01 by a paired two-tailed t test. F, Pathway of EPA metabolism leading to 
downstream metabolites including the biosynthesis of RvE1 and its receptors. Data were mined from the 1000 genomes and dbSNP human variants 
databases. Analyses show SNPs in the EPA and RvE1 metabolizing genes stratified by each minor allele (A,C,G,T). SNPs are depicted for (G) 
CYPs and (H) COX, 5-LOX, ALOX 12/15, FLAP, LTA4H, ChemR23, and BLT1. The SNPs in each gene are plotted by minor allele frequencies 
and the chromosome that contains the SNP. The major genes that metabolize EPA and/or RvE1 are depicted by differing colors
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the biosynthesis of select SPM precursors.40 Moreover, LA's 
consumption in the western diet is 14-18 times the amount 
required to prevent LA deficiency 2,41 and LA's effects on 
insulin sensitivity are debated.42 LA is an essential signaling 
PUFA for human and animal health, but its overconsumption 
may contribute toward chronic inflammation and metabolic 
impairments.
The data with EPA ethyl esters challenge previous find-
ings. Earlier studies reported a reduction in fat mass with 
EPA-containing oils, which we did not observe.35,43 The dif-
ferences in results using EPA ethyl esters compared to previ-
ous findings on body weight maybe due to the concentration/
purity of EPA, duration, and use of EPA/DHA mixtures. EPA 
driving an upregulation in the concentration of RvE1's pre-
cursor is highly consistent with a recent clinical trial to show 
that consumption of an n-3 PUFA supplement promoted a 
strong upregulation of SPMs within 24 hours.44
A major advancement is that our data show RvE1 could 
improve hyperinsulinemia and hyperglycemia via ERV1/
ChemR23. RvE1 treatment is likely exerting its effects 
through multiple mechanisms. There is evidence that RvE1 
blocks signaling through BLT1, the receptor for the arachi-
donic acid-derived LTB4.15 The pro-inflammatory mediator 
LTB4 serves as a chemokine for select immune cell popu-
lations that exacerbate glucose intolerance, particularly in 
white adipose tissue.45 We did not find evidence that RvE1 
is targeting the enrichment of immune cell populations in the 
adipose tissue as reported for resolvin D1.12 Therefore, RvE1 
must be targeting immune cells in other metabolic tissues as 
discussed below. The data are consistent with a study to show 
that protectin DX could improve insulin resistance indepen-
dent of an effect on adipose tissue inflammation.16 We did 
find that RvE1's parent compound EPA lowered some n-6 
PUFA-derived mediators, which could also influence the 
long-term inflammatory milieu.
Resolvin E1 activation of ERV1/ChemR23 may be fur-
ther inhibiting signaling through chemerin, an adipokine 
that binds ERV1/ChemR23.46 At the organ and cellular 
level, RvE1 can improve inflammation though the targeting 
of intestinal alkaline phosphatase and specific cell types in-
cluding neutrophils as well as through the production of fur-
ther downstream metabolites such as 18-oxo-RvE1.31,34,47,48 
The effects of RvE1 are likely to occur simultaneously with 
other EPA-derived metabolites. Notably, we observed EPA 
strongly upregulated the concentration of 12-HEPE, which 
was recently identified to improve glucose metabolism.49 In 
addition, EPA may also be exerting its effects through RvE2 
and RvE3, which is an area of future investigation.
There is some ambiguity among studies regarding the ef-
fects of RvE1 on hyperglycemia. Overexpression of ERV1/
ChemR23 in myeloid cells improved hyperglycemia and he-
patic steatosis of male mice.50 However, RvE1 administration 
to WT mice at a dose of 2ng/g body weight twice weekly for 
4 weeks did not improve hyperglycemia.50 Our studies relied 
on a higher dose of RvE1 (300ng/mouse) for four consecu-
tive days, which may explain the positive effects. Overall, our 
data on RvE1 were in agreement with the literature to show 
that select DHA-derived SPMs such as protectin DX and re-
solvin D1 improve insulin resistance and enhance glucose 
tolerance.12,16,32,51-53
Given the robust effect of RvE1 on hyperinsulinemia, we 
speculate that RvE1 could be targeting pancreatic islet size 
and insulin secretion from beta cells. To support this possibil-
ity, the Van Dyke group showed that myeloid overexpression 
of ERV1/ChemR23 led to an increase in the proportion of 
islet insulin-producing cells and islet size relative to mice on 
a HF diet 50 The underlying mechanism may be driven by 
improvements in pancreatic macrophage-driven inflamma-
tion, which was recently identified to be a major driver of 
impairments in insulin secretion.54 In support of this view, 
there is evidence from an in vitro study that RvE1 treatment 
lowers the expression of pro-inflammatory markers in human 
islets. Furthermore, ERV1/ChemR23 activation stimulates 
ERK phosphorylation and calcium influx in the pancreas.55,56 
Therefore, our studies set the basis for studying distinct in-
flammatory populations in the pancreas such as intra-islet 
and peri-islet macrophages that control insulin secretion.54 It 
is important to note that RvE1 may also be targeting other 
aspects of insulin and glucose metabolism as is relates to the 
liver and skeletal muscle.
A final advancement from this study is that DO mice, 
which model human genetic diversity, respond in a divergent 
manner upon RvE1 administration. The results open a new 
area of investigation by suggesting that RvE1 is unlikely to 
have a uniform positive effect in all obese humans. These 
results underscore the need for precision treatment in the 
human population. A future direction with the DO mice is 
to establish quantitative trait loci that control the metabolic 
response to RvE1 in obesity. This will set the basis for val-
idating key genes using genetically modified mouse models 
and analyses of human SNPs. Overall, little is known about 
the role of host genetics on SPM biology. One study high-
lights the importance of genetic variation by demonstrating 
that obese subjects with a C allele in the rs1878022 polymor-
phism of ERV1/ChemR23 receptor confers protection from 
adipose tissue inflammation.57
The study with DO mice directly informs emerging clin-
ical trials with EPA-derived metabolites on the need to ac-
count for the host genome. To exemplify, a recent placebo 
controlled randomized trial with a 15-hydroxy EPA ethyl 
ester (Epeleuton) showed an improvement in glycemic con-
trol, HbA1c, and inflammation in adults with nonalcoholic 
fatty liver disease.58 Therefore, future studies that account for 
host genetics may find more robust effects with the use of 
precision clinical trials. The results with the DO mice provide 
strong groundwork for studies that will establish candidate 
   | 15PAL et AL.
genes regulating the metabolic response to RvE1. This will 
allow investigators to establish “responders” from “non-re-
sponders” to EPA-derived metabolites in humans.
Mining the 1000 genomes and dbSNP databases re-
vealed a large range of minor allele frequencies in the 
EPA- and RvE1-metabolizing genes. Most of the genes 
analyzed reach minor allele frequencies close to 50%, in-
dicating large population variance in the EPA-RvE1 path-
way. Furthermore, close proximity of the CYP450 enzyme 
SNPs suggest potential genetic linkage in many of the 
CYP450 variants that can potentially influence metab-
olism of EPA and its downstream metabolites. There are 
numerous polymorphisms in the CYP enzymes related 
to various metabolic diseases.59 For instance, CYP2C8, 
CYP2C9, and CYP2C19 contain SNPs that have been as-
sociated with increased susceptibility to type 2 diabetes in 
the Indian, Japanese, and Saudi populations.60-63 The eti-
ology and risk of developing type 2 diabetes has also been 
associated with the COX2 rs5275 variant in type 2 diabetic 
patients.64 Furthermore, SNPs in FLAP or LTA4-H are cor-
related with a two-fold risk for myocardial infarction and 
stroke.65,66 SNPs in 5-LOX (ALOX5) have also been asso-
ciated with modest increases in body mass index.67 These 
studies highlight the importance of understanding genetic 
variants in the RvE1 response as numerous polymorphisms 
in the EPA metabolic pathway are common with potential 
clinical implications.
In summary, the results provide strong evidence that the 
EPA-RvE1 axis has a critical role in controlling insulin and 
glucose homeostasis, which may be a preventative target for 
cardiometabolic diseases. The results across model systems 
highlight the need for future prevention and treatment studies 
that account for the role of host genetics in the metabolism of 
RvE1 and other EPA-derived metabolites.
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